HEMOTİTİK ÜREMİK SENDROM 

Tanım: Hemolitik üremik sendrom (HÜS), mikroanjiopatik hemolitik anemi, trombositopeni ve akut böbrek yetmezliği ile karakterize bir trombotik mikroanjiopatidir. 

Gerekçe: Terapötik plazmaferez ile otoantikorlar ve mutasyona uğramış dolaşan kompleman regülatörleri dolaşımdan uzaklaştırılabilir. 

İşlem: TPD, DFPP, CF 

İşlenen Volüm: 1-1.5 TPH 

Sıklığı: Günlük 

Replasman Sıvısı: TDP veya albumin (T aktivasyon ilişkili HUS) 

Uygulama sayı ve/veya süresi: Standart bir yaklaşım olmamakla birlikte TTP‘de kullanılan uygulama yaklaşımı HÜS için adapte edilmiştir. Bu konuda Avrupa grubunun yaklaşımı da kullanılabilir: Ardışık 5 günlük 5 iĢlemi takiben 2 hafta boyunca haftada 5 işlem daha sonra haftada 3 işlem yapılıp 33. günde yeniden değerlendirilmelidir. Tedavinin devamına veya kesilmesine tedavi yanıtı ve hasta kliniğine göre karar verilmelidir. 

YARARLANILAN LİTERATÜRLER

*Banatvala N, Griffin PM, Greene KD, Barrett TJ, Bibb WF, Green JH, Wells JG. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001;183: 1063–1070. 

*von Baeyer H. Plasmapheresis in thrombotic microangiopathyassociated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 2002;6:320–328. 

*Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589–600. 

*Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, Ferrara J, Soiffer R, Giralt S. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571– 575.

*Zheng X, Sadler JE. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. In: Young NS, Gerson SL, High KA, editors. Clinical Hematology, 1st ed. Philadelphia: Mosby Elsevier. 2006. p 802–813. 

*Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60–68. 

*Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor MC, van de Kar N, Zimmerhackl LB. European Paediatric Research Group for HUS. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Internat 2006;70:423–431. 

*Zimmerhackl LB, Besbas N, Jungraithmayr T, van de Kar N, Karch H, Karpman D, Landau D, Loirat C, Proesmans W, Prufer F, Rizzoni G, Taylor MC. European Study Group for haemolytic uraemic syndromes and related disorders. Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 2006;32:113–120. 

*Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108: 1267–1279. 

*Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 2006;6:1948–1952.

*Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C. French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Society Nephrol 2007;18:2392–2400. 

*Hopkins CK, Yuan S, Lu O, Ziman A, Goldfinge D. A severe case of atypical hemolytic uremic syndrome associated with pneumococcal infection and T activation treated successfully with plasma exchange. Transfusion 2008;48:2448–2452. 

*Kwon T, Dragon-Durey MA, Macher MA, Baudouin V, Maisin A. Peuchmaur M.Fremeaux-Bacchi V, Loirat C. Successful pre-transplant management of a patient with anti-factor H autoantibodies- associated haemolytic uraemic syndrome. Theresa. 

Nephrol Dial Transplant 2008;23:2088–2090. 

*Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM. Thrombomodulin mutations in atypical hemolytic—uremic syndrome. N Engl J Med 2009;361:345–357. 

*Tarr PI. Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: distinct mechanisms of pathogenesis. Kidney International 2009;75(Suppl 112):S29–S32. 

*Bitzan M. Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Internat 2009;75(Suppl 112):S62–S66. 

*Watt T, Warshaw B, Katzenstein HM. Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin. Pediatr Blood Cancer 2009;53:90–126. 

*Hirt-Minkowski P, Schaub S, Mayr M, Schifferli JA, Dickenmann M, Fremeaux-Bacchi V, Steiger J. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? Nephrol Dial Transplant 2009;24:3548–3551. 

*Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB. European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009;24:687–696. 

*Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 115(2):379-87, 2010 Jan 14. Blood 2010;115:379–387. 

*Sullivan M, Erlic Z, Hoffmann MM, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Rybicki LA, Bock A, Berisha G, Neumann HPH. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet 2010;74:17–26.